Purpose: Fludarabine phosphate is effective as a single agent in low-grade non-Hodgkin's lymphoma (NHL). Combined with other antineoplastic agents it enhances the antitumor effect. Our aim was to define the therapeutic efficacy and toxicity of a combination of fludarabine, cyclophosphamide and dexamethasone (FluCyD) in patients with advanced low-grade lymphoma.
Introduction
Even though clinically responsive to initial treatment, most patients with advanced-stage low-grade nonHodgkin's lymphoma (LG-NHL) suffer relapse and need retreatment. Among the new agents, the purine analog fludarabine phosphate has been identified as particularly effective in LG-NHL. Fludarabine used as a single agent was effective in patients with recurrent low-grade lymphoma [1] . The overall response rates ranged from 31% to 38% in the larger series [2] [3] [4] . Smaller series have reported response rates from 52% to 67% [5] [6] [7] . A 30% response rate has been reported in pretreated mantle cell lymphoma [8] . Using fludarabine as a single agent in previously untreated patients with advanced follicular lymphoma a 65% response rate was obtained [9] . In view of these encouraging results, attempts are being made to enhance the antitumor activity of fludarabine through combination of this drug with other antineoplastic agents. The finding that fludarabine is a potent inhibitor of repair of DNA damage [10] constitutes the biological basis for the use of fludarabine in combination with DNA damaging agents. Although there have been no prospective randomized trials, phase II studies suggest improved clinical efficacy of fludarabine in combination with other agents. McLaughJin et al. [11, 12] investigated a combination of fludarabine, mitoxantrone and dexamethasone in recurrent or refractory indolent lymphoma, reporting an overall response rate of 94%. The efficacy of this regimen was confirmed by others [13] . Fludarabine and idarubicin therapy also appears to have promising activity for the treatment of recurrent indolent lymphoma [14] . The combination of fludarabine with cyclophosphamide has proven active in chronic lymphocytic leukemia [15] , and produced high response rates in previously untreated LG-NHL [16] [17] .
We initiated a phase II non-randomized study to define the therapeutic efficacy and toxicity of a combination of fludarabine, cyclophosphamide and dexamethasone (FluCyD) in patients with recurrent indolent lymphoma. Here we report on 25 patients first treated, focusing on the antitumor activity, the associated myelosuppression, and the immunological effects of this combination.
Patients and methods

Patients
Twenty-five adult patients with pretreated advanced LG-NHL entered this study between June 1996 and September 1997. The following histologic subtypes defined according to the R.E.A.L. Classification of non-Hodgkin's lymphoma were eligible: small lymphocytic; lymphoplasmacytoid; follicle center cell, follicular; mantle cell; nodal marginal zone lymphoma. Secondary transformed low-grade lymphomas were excluded on the basis of lymphoma biopsies performed in all patients at pre-study evaluation. Informed consent was obtained from all patients. Patients with prior exposure to fludarabine or other purine analogs were excluded. Eligibility criteria included age less than 75 years, Ann Arbor stage III or IV disease, absence of infections, adequate liver and renal function, hemoglobin level > 10 g/dl, granulocyte count > 1,000/ul, and platelet count > 80,000/|il. Patients with platelet counts of less than 80,000/ |il were considered eligible for this study if thrombocytopenia was the result of extensive marrow involvement by lymphoma. Pretreatment staging investigation included complete serum chemistry with LDH and p 2 -microglobulin level, chest X-ray, and bone marrow biopsy in all patients. Computed tomography (CT) scan of chest, abdomen and pelvis was performed in 16 patients; ultrasound study of the abdomen and pelvis in 9 patients.
Treatment
Treatment consisted of a combination of fludarabine 25 mg/m 2 /day (by i.v. infusion over 30 minutes) on days 1 to 3, cyclophosphamide 350 mg/m 2 /day i.v. on days 1 to 3, and dexamethasone 20 mg/day i.v. on days 1 to 3. The three-day course was repeated every four weeks. Patients were scheduled to receive six courses. The course was delayed if granulocyte count was < 1,000/ul or platelets were <80,000/ul, or in case of infection. No reduction of the planned dose was permitted. Treatment was discontinued if hematologic toxicity caused a delay of the subsequent course longer than three weeks, or in instances of severe toxicity or disease progression. No granulocyte or granulocytemacrophage colony-stimulating factors were given. Oral allopurinol and appropriate hydration were given during the first three courses. Trimethoprim-sulphametoxazole was given two days per week for prophylaxis of Pneumocystis carinii pneumonia during the entire duration of treatment and for three months following the last course.
Patient monitoring, response and toxicity
A full blood count was performed weekly during treatment and monthly after completion of therapy. Patients were reassessed after four courses and one month after completion of treatment by reiteration of the pretreatment investigations, including bone marrow biopsy. Responding patients who withdrew prematurely because of toxicities were evaluated for response after resolution of the toxic effects. Complete response (CR) was defined as the disappearance of all clinical evidence of disease. Partial response (PR) required a > 50% decrease in measurable disease for at least one month without the appearance of new lesions. Any other responses including stable disease, progressive disease, early death, or death from toxicity were considered treatment failures. Progression was defined as an increase by more than 25% in measurable disease. Toxicity was evaluated and graded according to World Health Organization (WHO) criteria. The immunologic effects of treatment were evaluated by serial measurement of peripheral CD4+ lymphocyte count by fluorescence-activated cell sorter analysis. The effect of treatment on Epstein-Barr virus (EBV) infection reactivation was monitored in 10 patients last treated by measurements of the number of copies of EBV genome/100,000 peripheral blood mononuclear cells (PBMC). Measurements were made at the start of each course and after completion of therapy by a quantitative PCR assay for viral DNA quantification. This methodology is derived from a previously reported method developed for human cytomegalovirus DNA quantification [18] and includes the use of an internal amplification control and a series of external standards which are amplified in parallel with test samples (manuscript in preparation). A direct antiglobulin test was performed every three courses and at completion of treatment. After treatment, patients were examined every three months. Survival was calculated from the date of entering the study until death from any cause. Failure-free survival was calculated from entry into the protocol until treatment failure (disease progression, relapse, or toxic death). Relapse-free survival for responding patients was calculated from the date of response until relapse. Survival curves were calculated according to the method of Kaplan and Meyer.
Results
Patient characteristics
The clinical features of the 25 patients treated in the study are listed in Table 1 . The median age was 54. The histology according to the R.E.A.L. Classification of non-Hodgkin's lymphoma was: Follicular center cell, follicular in 14, lymphoplasmacytoid in four, small lymphocytic in three, mantle cell in three, nodal marginal zone in one. The median interval since diagnosis was 42 months. Patients had previously been treated with a median of two chemotherapy regimens (range 1-4). Prior treatments included anthracycline in 23 patients. Seven patients had relapsed from unmaintained CR and 18 had progressed from a previous PR. In 13 of these last, the disease progressed during maintenance with alfainterferon or chlorambucyl. Of 25 patients, 19 (76%) had bone marrow involvement, and in 10 patients (40%) more than 50% of marrow cells were lymphoma cells. At the start of FluCyD, six patients had platelet counts of less than 80,000/uI associated with marrow involvement (in these patients the median percentage of BM infiltration was 75%, range 55%-95%); four of them also had granulocyte counts of 1,000 to 1,500/ul.
Response
Of 25 patients, 18 responded, for an overall response rate of 72%, 8 (32%) achieving a CR and 10 (40%) a PR ( Table 2) . Of 18 responders, 12 could receive the planned six courses, while six patients received from two to five courses because of hematologic toxicity lasting longer than 3 weeks. The median number of courses to maximum response was four (3-6) for patients achieving CR, and four (1-6) for those achieving only a PR. Seven patients were failures. Of these, four showed disease unchanged after four to six courses, so they were considered treatment failures. Three patients required discontinuation of therapy after the first course because of prolonged thrombocytopenia, and granulocytopenia associated with infection in two of them: one had pneumonia and 1 developed septicemia, which was the only treatment-related death. After the last course, responders were followed until relapse or progression without receiving further treatment. The median follow-up time for the 18 surviving patients was 21 months (5-26 months). The failure-free survival curve for all patients is shown in Figure 1 . The median failure-free survival was 21 months for responders and nine months for non-responders. All eight of the CR patients remain in CR after periods of 5-21 months from response. Of the 10 PR patients, three have been in continuous PR for periods of 12, 17, 18 months and seven have developed progressive disease. The relapsefree survival of the 18 responders is 53% at 18 months. Of the seven progressions, five occurred early (two, three, three, four, and six months after achievement of PR) and two after 16 and 17 months, respectively. Four patients progressed as high-grade NHL. One of these, with lymphocytic lymphoma, who had achieved a PR with two courses, at the end of the fifth cycle rapidly developed histologically documented diffuse large-cell 10 15 Months Figure 1 . Failure-free survival of 25 patients treated with the FluCyD combination. lymphoma. One patient with follicular lymphoma progressed to diffuse large-cell histology with bulky inguinal masses two months after completion of six courses of therapy. In both patients FluCyD treatment was complicated by Herpes-Zoster Virus (HZV) infection. Two patients, one with follicular and one with mantle cell NHL, progressed to diffuse large-cell histology after four and six months, respectively. Three patients progressed, retaining a low-grade histology after 3, 16, and 17 months. Three patients who progressed did not respond to salvage treatments and died within three months.
Hematologic toxicity
A total of 119 courses were assessable for toxicity. Myelosuppression was the prevailing toxic effect of treatment. The median granulocyte and platelet nadirs for each course are reported in Table 3 . Granulocyte and platelet count nadirs were significantly lower after the sixth course than after the first course. Absolute granulocyte counts of <500/ul and platelet counts of <50,000/ul occurred in only 10% and 16% of courses, respectively. However, 40% of the courses had to be delayed beyond the planned four-week interval because of slow granulocyte or platelet count recovery. Nine patients required discontinuation of therapy because of prolonged myelotoxicity (granulocytopenia and/or thrombocytopenia lasting more than three weeks): three after one course; one each after two, three, and four courses; three after five courses. In responders, the median bone marrow cellularity evaluated on restaging biopsies performed one to two months after the end of treatment was 40% (range 20%-60%). One CR patient underwent peripheral blood stem cell mobilization with high-dose cyclophosphamide and G-CSF but the CD34+ cell collection was unsuccessful. Infections: 13 infectious episodes occurred in 11 patients, complicating 11% of courses. There were two pneumonias by unknown agent, two bronchitis, two HZV infections, one HSV infection, one septicemia, and five febrile episodes of clinically suspected infectious origin in the context of neutropenia. No significant infectious episodes occurred in responding patients between completion of treatment and relapse or progression.
Of 10 patients serially monitored for the circulating EBV load, eight showed a stable number of EBV genomes ( < 10/100,000 PBMC) for the entire period of observation. One patient with lymphocytic lymphoma showed an increase in EBV genome copies in peripheral blood to 1,000/100,000 PBMC concurrently with development of aggressive lymphoma with bulky abdominal masses. The study of abdominal lymph node biopsy showed positive PCR for Bam W of DNA EBV whereas immunohistochemistry with monoclonal antibodies to LMP-1, EBNA-2, and ZEBRA, and in situ hybridization for EBERs (Dako) were negative. Another patient with nodal marginal zone lymphoma had an increase in EBV genome copies in peripheral blood to 1,500/100,000 PBMC by the third course. Two months after discontinuation of therapy for non-response to four courses, the viral load rose to 3,000/100,000 PBMC with stable disease. At this point, a biopsy of superficial lymph nodes confirmed the nodal marginal zone lymphoma histology. A PCR assay for Bam W was positive, while immunohistochemical study with monoclonal antibodies to LMP-1, EBNA-2, and ZEBRA, and in situ hybridization for EBERs were negative. In this patient, five months after the end of therapy the number of EBV genomes had decreased to 100/100,000 PBMC. Table 4 shows the behavior of the absolute CD4+ lymphocyte count in 16 patients treated with at least three courses of FluCyD who had CD4+ lymphocytes monitored before treatment, after three courses, and at the end of therapy. Many of these patients also had CD4+ lymphocyte counts monitored three and six months after completion of therapy. The CD4+ lymphocyte count declined from a median pre-therapy value of 425/ul to a median post-treatment value of 141 /ul (P = 0.001, Wilcoxon matched pairs test).
Non-hematologic toxicity
Non-hematologic toxicities were rare and generally mild. Nausea was reported in only 8% of courses and no patients reported vomiting. Two patients, aged 35 and 66, experienced neurotoxicity as peripheral neuropathy which resolved completely within six weeks. None of the patients presented alopecia. There were no instances of hepatic, renal, cardiac, or pulmonary toxicity attributable to FluCyD. No patients developed autoimmune hemolytic anemia.
Discussion
This study shows that the combination of fludarabine with cyclophosphamide and dexamethasone is an effective treatment for patients with recurrent indolent NHL. The 25 patients treated in this study were all in advanced phase and many of them entered the study cytopenic because of extensive marrow involvement. Of these patients 72% responded to FluCyD, 32% achieving a CR and 40% a PR. The median failure-free survival of responders is 21 months. The complete responders have remained disease-free for periods of 5-21 months. Given that the subset of patients treated in this study is particularly difficult, the overall response rate is satisfactory. It seems higher than that obtained in the largest previous studies with fludarabine alone [2] [3] [4] , and similar to that of other studies which combine fludarabine with mitoxantrone [11] [12] [13] , with idarubicin [14] , or with paclitaxel [19] , in relapsed or recurrent low-grade NHL. The combination of fludarabine with cyclophosphamide has been shown to produce high response rates and durable progression-free survival in previously untreated low-grade NHL [16] [17] . Our study demonstrates its efficacy also in pretreated advanced-phase patients with recurrent disease. The median follow-up period is still relatively short for judging the capacity of this regimen to maintain long-term disease-free survival.
The FluCyD combination was well tolerated with almost no acute nonhematologic toxicities such as nausea and vomiting. The most frequent toxic effect of treatment was myelosuppression. Because of slow granulocyte or platelet count recovery, 40% of the courses were delayed and nine patients required early discontinuation of therapy because of prolonged myelosuppression. Absolute granulocyte count nadir of < 500/ul and platelet count nadir of < 50,000/ul occurred in 10% and 16% of the courses, respectively. Nevertheless, only 11% of the courses were complicated by infection. Myelosuppression might have been favored by advanced disease, multiple prior treatments, massive marrow involvement, poor marrow reserve. This protocol did not call for the use of colony-stimulating factors. Their use might lessen neutropenic infectious complications and permit adherence to the planned schedule.
As observed following fludarabine alone, blood CD4+ lymphocyte count declined significantly after FluCyD treatment and remained at low levels for months after completion of therapy (Table 4) . The profound and longlasting CD4 suppression, however, was not associated with a higher incidence of opportunistic infections than that expected in similar patients treated with salvage regimens. The absence of cases of Pneumocystis carinii pneumonia infection might be the result of the trimethoprim-sulphametoxazole prophylaxis. In contrast to CLL, fludarabine-related immune deregulation in LG-NHL patients did not lead to the emergence of autoimmune phenomena. After fludarabine treatment for LG-NHL, scattered cases have been reported of EBVassociated transformation to high-grade NHL apparently related to immunosuppression [20] . In this study, monitoring for the circulating EBV loads in peripheral blood of ten patients showed in one patient an increase to 1,000/100,000 PBMC concurrently with development of aggressive lymphoma, and in another patient an EBV level fluctuation with increase up to 3,000/100,000 PBMC without histologic progression. In both cases immunohistochemical and in situ hybridization studies were not consistent with an EBV-related lymphoproliferation. The PCR positivity for EBV DNA could be related to the presence of EBV-infected bystander cells [21] .
Fludarabine in association with cyclophosphamide is increasingly being investigated for its immunosuppressive potential in the context of preparative regimens for allogeneic stem cell transplantation [22] . Our findings, although preliminary, indicate that monitoring for EBV reactivation may be of value after fludarabine-containing regimens.
In conclusion, this study shows that fludarabine in combination with cyclophosphamide and dexamethasone is effective in pretreated advanced-stage low-grade NHL. It may broaden the range of therapeutic options in the salvage treatment of these patients. The main toxicity of this combination is prolonged myelosuppression that may cause treatment delay or early withdrawal. The benefit of adding granulocy te colony-stimulating factor, particularly in patients with poor marrow reserve, remains to be evaluated with further patient accrual. Other points to investigate are: the optimal duration of treatment, the possibility of collecting peripheral stem cells for high-dose consolidation of responses, and the clinical significance of the post-fludarabine immunological dysfunction associated with decrease of CD4+ cells.
